Manufacturing Viral Vectors for the Next Phase of CGT

As the sector matures, scalable vector production and robust analytical control are becoming essential to clinical and commercial success

Category	Detail
Condition	Cell and Gene Therapies (CGTs)
Key Mechanisms	Advances in viral vector technologies (AAV, LV, RV) for therapeutic applications.
Target Population	Patients requiring gene and cell therapies across oncology, neurology, and rare diseases.
Care Setting	Clinical and manufacturing environments for CGT development.

38 gene therapies, 36 RNA therapies, and 71 non-genetically modified cell therapies approved globally.
Manufacturing capability is a critical factor for the success of CGT programs.
Early design choices in vector manufacturing significantly impact scalability and regulatory compliance.
Robust analytics are essential for monitoring quality attributes and regulatory submissions.
Speed and sustainability must be balanced to avoid compromising long-term success.

Align process architecture and materials with intended scale early in development.

Address variability and sensitivity to processing conditions in vector manufacturing.

Patients with rare diseases or broader indications requiring CGT.

Production volumes vary significantly based on disease indication and patient needs.

Proactive planning for GMP-grade plasmids to avoid delays.
Early alignment on cell substrates and raw materials for smoother transitions.
Design processes with future GMP expectations to minimize redesign needs.
Utilize platform analytics to support consistent monitoring across development phases.
Focus on strategic acceleration rather than short-term speed compromises.